Multiple Sclerosis-Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Multiple Sclerosis-Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

  • 168 Pages | 30-Jan-19 | Format:PDF | Last Updated: 30-Jan-19
  • GervanoRA’s pipeline analysis and opportunity assessment report “Multiple Sclerosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Multiple Sclerosis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Multiple Sclerosis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Epidemiology and Epidemiology forecast till 2023
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Marketed drugs
    • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2 EXECUTIVE SUMMARY
    2.1. REPORT MAJOR FINDINGS
    2.2. KEY PIPELINE EVENTS (REGULATORY APPROVALS) 2018 – 2034
    3 DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. TREATMENT ALGORITHM AND GUIDELINES
    3.4. EPIDEMIOLOGY AND DISEASE BURDEN
    3.5. EPIDEMIOLOGY FORECAST
    3.5.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    3.5.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4 MARKET OVERVIEW
    4.1. DEALS (MERGERS /ACQUISITIONS/COLLABORATIONS)
    4.1.1. ACQUISITIONS AND MERGERS
    4.1.2. COLLABORATION AGREEMENTS
    4.1.3. LICENSING AGREEMENTS
    4.1.4. FINANCING DEALS
    4.1.5. TERMINATION AGREEMENTS AND SETTLEMENTS
    4.2. NEW DRUG APPROVALS (EMA OR EX-US) SINCE 2010
    4.3. NEW DRUG APPROVALS (US FDA) SINCE 2010
    4.4. MULTIPLE SCLEROSIS APPROVED DRUG’S PATENT ANALYSIS
    5 PIPELINE ANALYSIS
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL STAGE OF DEVELOPMENT MOLECULES
    5.1.6. EARLY R&D (DISCOVERY)
    5.2. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY DRUG CLASS
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE MOLECULES BY COMPANIES, UNIVERSITIES AND INSTITUTES
    5.5.1. PIPELINE MOLECULES DEVELOPING BY COMPANIES
    5.5.2. PIPELINE MOLECULES DEVELOPING BY UNIVERSITIES AND INSTITUTES
    6 ESTIMATED APPROVAL TIMELINES
    6.1. METHODOLOGY
    6.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    7 CLINICAL TRIAL SUMMARY
    7.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    7.1.1. KEY PHASE 3 CLINICAL TRIAL RESULTS
    7.1.2. KEY PHASE 2 CLINICAL TRIAL RESULTS
    7.2. ONGOING CLINICAL TRIALS SUMMARY
    7.2.1. PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    7.2.2. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    7.2.3. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
    7.3. PLANNED CLINICAL TRIALS SUMMARY
    7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS (2015-2018)
    7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS (2016-2017)
    7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS (2015-2018)
    7.5. WITHDRAWN AND TERMINATED CLINICAL TRIALS
    7.5.1. WITHDRAWN TRIALS
    7.5.2. TERMINATED TRIALS
    8 CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    8.1. ESTABLISHED COMPANIES
    8.2. ESTABLISHED COMPANY PROFILES AND SWOT
    8.2.1. SANOFI
    8.3. EMERGING COMPANIES
    8.4. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES
    8.4.1. REDHILL BIOPHARMA LTD
    8.4.2. FLEX PHARMA, INC.
    8.4.3. ABIDE THERAPEUTICS
    8.4.4. BRAINSTORM CELL THERAPEUTICS
    8.4.5. ATARA BIOTHERAPEUTICS
    8.4.6. ENDECE, LLC
    8.4.7. COMMENCE BIO INC.
    8.4.8. VACCINEX
    8.4.9. SANBIO
    8.4.10. Q THERAPEUTICS
    8.4.11. BOLDER BIOTECHNOLOGY, INC
    8.4.12. ARTIELLE IMMUNOTHERAPEUTICS
    8.4.13. ONCOIMMUNE
    8.4.14. CELLIXBIO
    8.4.15. AKAAL PHARMA PTY LTD
    8.4.16. VIRTICI, LLC
    8.4.17. MAPI-PHARMA LTD
    8.4.18. IO THERAPEUTICS, INC
    8.4.19. ARRIEN PHARMACEUTICALS
    8.4.20. REVERAGEN BIOPHARMA
    8.4.21. NUTRA PHARMA CORPORATION
    8.4.22. REGENERX BIOPHARMACEUTICALS, INC.
    8.5. UNIVERSITIES AND INSTITUTES
    9 ABBREVIATIONS

    LIST OF TABLES

    TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 02: DATA SHOWING TOTAL NUMBER OF PEOPLE HAVING MS, PREVALENCE, MEAN ONSET OF AGE AND FEMALE TO MALE RATIO
    TABLE 03: DATA SHOWING TOTAL NUMBER OF PEOPLE HAVING MS, PREVALENCE, MEAN ONSET OF AGE AND FEMALE TO MALE RATIO IN EUROPEAN COUNTRIES
    TABLE 04: GLOBAL MS EPIDEMIOLOGY (2016), FORECAST (2017-2023)
    TABLE 05: MAJOR ACQUISITIONS IN MS THERAPEUTIC AREA
    TABLE 06: MAJOR COLLABORATIVE AGREEMENTS IN MS THERAPEUTIC AREA
    TABLE 07: MAJOR LICENSING AGREEMENTS IN MS THERAPEUTIC AREA
    TABLE 08: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN MS THERAPEUTIC AREA
    TABLE 09: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN MS THERAPEUTIC AREA
    TABLE 10: EMA OR EX-US DRUG APPROVALS SINCE 2010
    TABLE 11: US FDA APPROVED DRUGS SINCE 2010
    TABLE 12: GILENYA PATENTS
    TABLE 13: TECFIDERA PATENTS
    TABLE 14: PLEGRIDY PATENTS
    TABLE 15: AMPYRA/FAMPYRA PATENTS
    TABLE 16: AUBAGIO PATENTS COVERAGE AND EXPIRY
    TABLE 17: LEMTRADA PATENTS COVERAGE AND EXPIRY
    TABLE 18: ZYNBRYTA PATENTS
    TABLE 19: SUMMARY OF COMPANY PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
    TABLE 20: FILING/UNDER REVIEW MOLECULES
    TABLE 21: LIST OF PIPELINE MOLECULES IN PHASE 3 DEVELOPMENT STAGE
    TABLE 22: LIST OF PHASE 2 MOLECULES
    TABLE 23: LIST OF PHASE 1 MOLECULES
    TABLE 24: LIST OF PRECLINICAL MOLECULES
    TABLE 25: LIST OF EARLY R&D MOLECULES
    TABLE 26: ORALLY ADMINISTERED KEY PIPELINE MOLECULES
    TABLE 27: INTRAVENOUSLY ADMINISTERED KEY PIPELINE MOLECULES
    TABLE 28: SUBCUTANEOUSLY ADMINISTERED KEY PIPELINE MOLECULES
    TABLE 29: LIST OF COMPANIES WITH PIPELINE MOLECULES IN DIFFERENT DEVELOPMENT STAGES
    TABLE 30: UNIVERSITY AND INSTITUTE’S PIPELINE MOLECULES FOR MS
    TABLE 31: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 32: POINT CLINICAL TRIALS STUDY DESIGN
    TABLE 33: OZANIMOD SUNBEAM STUDY RESULTS
    TABLE 34: OZANIMOD RADIANCE PART B STUDY RESULTS
    TABLE 35: ADVERSE EVENTS OF BIIB098/ALKS 8700 IN EVOLVE-MS-1 STUDY
    TABLE 36: EVOBRUTINIB (M2951) PHASE 2 CLINICAL TRIALS STUDY DESIGN
    TABLE 37: RHB-104 PHASE 2 CLINICAL TRIALS STUDY DESIGN
    TABLE 38: ANNUALIZED RELAPSE RATES (ARR) OF IN CEASE-MS STUDY OF RHB-104
    TABLE 39: ATX-MS-1467 – APITOPE PHASE 2 CLINICAL STUDY DESIGN
    TABLE 40: PHASE 3 ONGOING CLINICAL TRIALS
    TABLE 41: PHASE 2 ONGOING CLINICAL TRIALS
    TABLE 42: PHASE 1 ONGOING CLINICAL TRIALS
    TABLE 43: PLANNED CLINICAL TRIALS FOR MULTIPLE SCLEROSIS
    TABLE 44: RECENTLY COMPLETED PHASE 3 TRIALS (2015-2018)
    TABLE 45: RECENTLY COMPLETED PHASE 2 TRIALS (2016-2017)
    TABLE 46: RECENTLY COMPLETED PHASE 1 TRIALS (2015-2018)
    TABLE 47: WITHDRAWN CLINICAL TRIALS FOR MULTIPLE SCLEROSIS
    TABLE 48: TERMINATED CLINICAL TRIALS FOR MULTIPLE SCLEROSIS
    TABLE 49: SANOFI PRODUCT PORTFOLIO
    TABLE 50: INFLAMMATION AND IMMUNOLOGY PIPELINE PRODUCTS OF SANOFI
    TABLE 51: CARDIOVASCULAR & METABOLISM PIPELINE PRODUCTS OF SANOFI
    TABLE 52: DIABETES PIPELINE PRODUCTS OF SANOFI
    TABLE 53: MS AND NEURO PIPELINE PRODUCTS OF SANOFI
    TABLE 54: ONCOLOGY PIPELINE PRODUCTS OF SANOFI
    TABLE 55: RARE BLOOD DISORDERS PIPELINE PRODUCTS OF SANOFI
    TABLE 56: RARE DISEASES PIPELINE PRODUCTS OF SANOFI
    TABLE 57: VACCINES PIPELINE PRODUCTS OF SANOFI
    TABLE 58: R&D ACTIVITIES OF SANOFI
    TABLE 59: MILESTONES ACHIEVED BY SANOFI
    TABLE 60: CONFERENCES/EVENTS ATTENDED BY SANOFI
    TABLE 61: RECENT DEVELOPMENTS MADE BY SANOFI
    TABLE 62: UNIVERSITY AND INSTITUTE’S PIPELINE MOLECULES AVAILABLE FOR LICENSING

    LIST OF FIGURES

    FIGURE 01: KEY PIPELINE EVENTS, 2018-2034
    FIGURE 02: GLOBAL MS EPIDEMIOLOGY, CURRENT TREND AND FORECAST
    FIGURE 03: OVERALL DEALS ACTIVITY IN MS THERAPEUTIC AREA SINCE 2010
    FIGURE 04: MULTIPLE SCLEROSIS PIPELINE SPLIT BY HSD
    FIGURE 05: PIPELINE MOLECULES WITH ROUTES OF ADMINISTRATIONS
    FIGURE 06: UNIVERSTIY MOLECULES FOR MS BY PHASE OF DEVELOPMENT
    FIGURE 07: ANNUALIZED RELAPSE RATES OF OZANIMOD V/S INF IN SUNBEAM STUDY
    FIGURE 08: REDUCTION IN GADOLINIUM-ENHANCED MRI LESIONS WHEN USED OZANIMOD V/S INF
    FIGURE 09: REDUCTION IN NEW OR ENLARGING T2 LESIONS WHEN USED OZANIMOD V/S INF
    FIGURE 10: ANNUALIZED RELAPSE RATES OF OZANIMOD V/S INF IN RADIANCE PART B STUDY
    FIGURE 11: PERCENTAGE REDUCTION IN NEW OR ENLARGING T2 LESIONS BY USING OZANIMOD V/S INF IN RADIANCE PART B STUDY
    FIGURE 12: PERCENTAGE REDUCTION IN GADOLINIUM-ENHANCED MRI LESIONS BY USING OZANIMOD V/S INF IN RADIANCE PART B STUDY
    FIGURE 13: PERCENTAGE REDUCTION IN BRAIN VOLUME LOSS BY USING OZANIMOD V/S INF IN RADIANCE PART B STUDY
    FIGURE 14: ONGOING PHASE 3 TRIALS BY MS TYPE
    FIGURE 15: RECENTLY COMPLETED PHASE 3 TRIALS BY DISEASE TYPE
    FIGURE 16: RECENTLY COMPLETED PHASE 3 TRIALS BY MAJOR COMPANIES
    FIGURE 17: RECENTLY COMPLETED TRIALS, MAJOR COMPANIES V/S DISEASE TYPE
    FIGURE 18: RECENTLY COMPLETED PHASE 3 TRIALS BY DISEASE TYPE
    FIGURE 19: FINANCIAL INFORMATION OF SANOFI BY HEALTHCARE AREA (IN %)
    FIGURE 20: FINANCIAL INFORMATION OF SANOFI BY GEOGRAPHICAL AREA (IN %)
    FIGURE 21: SWOT ANALYSIS OF SANOFI

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)